Entrectinib

Overview

Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C , ROS1 and ALK , with IC 50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ROS Kinase | Products > Signaling Pathways > Trk Receptor | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-12678
• CAS No.: 1108743-60-7
• Molecular Formula: C31H34F2N6O2
• Molecular Weight: 560.64
• Purity: 98.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.46 mM); Clear solution
• Availability: In-stock

Source

Original product source